A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.

Silvana DebernardiHarrison O'BrienAsma S Algahmdi Núria Malats Grant D Stewart Marija Plješa-Ercegovac Eithne Costello William GreenhalfAmina SaadRhiannon Roberts Alexander Ney Stephen P Pereira Hemant Mahendrakumar Kocher Stephen W Duffy Oleg BlyussTatjana Crnogorac-Jurcevic

Published in: PLoS medicine (2020)

We have successfully validated our urinary biomarker panel, which was improved by substituting REG1A with REG1B. At a pre-selected cutoff of >80% SN and SP for the affiliated PancRISK score, we demonstrate a clinically applicable risk stratification tool with a binary output for risk of developing PDAC ('elevated' or 'normal'). PancRISK provides a step towards precision surveillance for PDAC patients, which we will test in a prospective clinical study, UroPanc.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
public health
prognostic factors
patient reported outcomes
ionic liquid